Pretomanid
FDA-approved product (tablet, oral), marketed as Pretomanid.
- Registered studies
- 49
- Lab records
- 57
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Drug-resistant tuberculosis
- Multidrug-resistant tuberculosis
- Pulmonary tuberculosis
- Tuberculosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for treatment of tuberculosis
- FDA pharmacologic class
- Antimycobacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J04AK08; FDA class Antimycobacterial
Repurposing investigation
Pretomanid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
49registered studies name this medicine, for any condition. See them below.
Experimental
- M. tuberculosis: measured active in 52 of 57 lab records
Show the 57 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Pretomanid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
NCT00567840 · start 2007-08
Registered record
- Registry ID
- NCT00567840
- Conditions
- Pulmonary Tuberculosis
- Interventions
- PA-824
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2007-12
- Enrolment
- 69
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary TuberculosisInterventionPA-824PhasePhase 2Registry statusCompletedFood Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects
NCT01828827 · start 2007-03
Registered record
- Registry ID
- NCT01828827
- Conditions
- Tuberculosis
- Interventions
- PA-824 1000 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-03
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionPA-824 1000 mgPhasePhase 1Registry statusCompletedA Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
NCT03202693 · start 2006-03
Registered record
- Registry ID
- NCT03202693
- Conditions
- Tuberculosis
- Interventions
- PA-824
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2006-05
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionPA-824PhasePhase 1Registry statusCompletedPharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00042289 · start 2003-06-09
Registered record
- Registry ID
- NCT00042289
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2003-06-09
- Completion
- 2020-09-30
- Enrolment
- 1,578
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 morePhaseNot recordedRegistry statusCompleted